Abstract:Molecularly directed targeted therapies have become a key component of caring for patients with metastatic solid tumors, both alongside and instead of conventional chemotherapy and immunotherapy. Treatment options for patients with advanced cancer have expanded dramatically over the past decade, with the development of a wide variety of targeted therapies for oncogene-addicted tumors and the demonstration of efficacy of immune checkpoint inhibitors for many cancer types. Cell-free circulating tumor DNA (ctDNA) is shed by tumor cells into the systemic circulation and, thanks to advancements in next-generation sequencing (NGS) technologies, affords the opportunity to noninvasively detect cancer-specific somatic variants. The use of ctDNA-based molecular genotyping for tumor profiling and identification of patients eligible for targeted therapies has been integrated into clinical practice for a variety of tumor types. The prime example of this is in non–small cell lung cancer (NSCLC), where identifying actionable variants via genomic profiling is essential to determining the appropriate standard of care for patients. The National Comprehensive Cancer Network recommends that all patients with metastatic NSCLC undergo molecular genotyping, and the European Society for Medical Oncology mandates testing for oncogenic drivers for which there are approved drugs. 1 ,2 Earlier approaches supported by the International Association for the Study of Lung Cancer prioritized tissue-based NGS at time of diagnosis, with ctDNA-based molecular genotyping relegated to the identification of resistance variants after progression on targeted therapy. 3 However, practical considerations, including faster resulting time, lower potential for sample inadequacy, and elimination of the need for invasive and, in some situations, prohibitively hazardous tissue sampling have led to the increased utilization of ctDNA molecular genotyping at diagnosis. 2 ,4 -6 Iams et al 6 report on a large, multi-institutional cohort evaluating the utility of a concurrent ctDNA-based and tissue-based molecular genotyping approach in a patient population with various metastatic cancers. The cohort consisted of 3209 patients with stage IV cancer: 1302 (41%) with NSCLC, 923 (29%) with colorectal cancer, 660 (20%) with breast cancer, and 324 (10%) with prostate cancer. Among 1448 patients found to have at least 1 actionable variant on tissue-based or ctDNA-based molecular genotyping, 135 (9.3%) had clinically actionable variants identified only in ctDNA testing. 6 This study has important implications and helps to solidify the added value of ctDNA-based molecular genotyping in identifying targetable variants that may not be recognized in tissue-only assessment. This finding highlights the utility of ctDNA-based genotyping in cases of intratumoral heterogeneity, as well as heterogeneity between a primary lesion and metastatic sites and can inform therapy selection. This study raises important practical questions. How should these results inform clinical practice? Should we use concurrent molecular genotyping across all solid tumors, and, if so, should testing be performed upon initial diagnosis, or at the time of progression? At present, the most substantial data supporting the use of concurrent ctDNA-based molecular genotyping to uncover actionable targets lies in NSCLC. Current NSCLC guidelines support the use of concurrent testing at time of initial diagnosis to decrease turnaround time and increase detection of targetable variants. 2 In addition, both the National Comprehensive Cancer Network and the European Society for Medical Oncology support the use of ctDNA testing at the time of diagnosis in specific clinical scenarios, including if patients are not fit to undergo invasive tissue sampling or when samples are inadequate for molecular analysis. Guidelines also support ctDNA molecular genotyping if initial tissue-based testing does not completely assess all recommended biomarkers due to tissue quantity or available testing methods. However, this recommendation includes the caveat that a repeat tissue-based analysis may be required if an oncogenic driver is not found. 1 ,2 Although the results presented by Iams et al 6 validate previously published findings in patients with metastatic NSCLC and support the use of concurrent ctDNA molecular genotyping in this population, open questions remain about how to translate these findings to other solid tumor types. In the subgroup of patients with breast cancer, 20.2% of actionable variants were uniquely identified by ctDNA-based molecular genotyping, with the majority consisting of ESR1 variants for which there was less than 50% tissue and ctDNA profiling based concordance. 6 On the basis of these results, for patients with breast -Abstract Truncated-

Abstract 2498: Assessing the clinical value of ctDNA sequencing for initial tumor profiling in metastatic colorectal cancer patients with sufficient tumor tissue

Clinical Significance of Circulating Tumor DNA in Neoadjuvant-Treated HER2-negative Luminal B Breast Cancer.

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Abstract LB547: Ultra-deep targeted sequencing of circulating tumor DNA with colorectal cancer patients for prediction of treatment response and post-surgical follow-up

Abstract 3380: Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer

Abstract 966: Longitudinal comparative analysis of circulating tumor DNA and matched tumor tissue DNA in patients with metastatic colorectal cancer receiving palliative first-line systemic anti-cancer therapy

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Abstract P2-02-06: Biomarker analysis by next generation circulating tumor DNA (ctDNA) sequencing in patients with advanced breast cancer

Abstract 2281: The role of baseline and early dynamics of ctDNA in predicting response and prognosis of early and advanced gastroesophageal adenocarcinomas

Abstract 5021: Circulating mutated and methylated tumor DNA detection for colorectal cancer diagnosis

ctDNA analysis in patients with cancer of unknown primary and its value in guiding targeted treatment when combined with predicted cancer types by 90-gene reverse-transcription polymerase chain reaction assay.

Blood-based genomic profiling of circulating cell-free tumor DNA (ctDNA) in 1397 patients (pts) with colorectal cancer (CRC).

Abstract 936: Targeted proteomics and next-generation sequencing (NGS) for biomarker discovery in metastatic colorectal cancer (mCRC)

Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for postoperative monitoring of patients with stages I-III colorectal cancer

Clinical value of sequential circulating tumor DNA analysis using next-generation sequencing and epigenetic modifications for guiding thermal ablation for colorectal cancer metastases: a prospective study

Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients

Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients

Concurrent ctDNA and Tissue Genotyping

Abstract PO4-01-04: Clinical significance of Circulating tumor DNA (ctDNA) analysis in predicting pathologic complete remission in HER2-positive Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Circulating Tumor DNA(ctDNA) Testing to Detect Identical Gene Mutation Rates of KRAS, NRAS, PIK3CA and P53 Compared to Tissue-Based Testing and Reflects Treatment Efficacy in Patients with Colorectal Cancer.

Clinical utility of upfront circulating tumor DNA (ctDNA) genotyping to guide first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): A GOZILA substudy.